MapLight Therapeutics holder to sell 18,835 shares

James Lillie plans to sell up to 18,835 shares of MapLight Therapeutics, Inc. common stock through broker Jefferies LLC.

Rhea-AI Filing Summary

James Lillie plans to sell up to 18,835 shares of MapLight Therapeutics, Inc. common stock through broker Jefferies LLC. The planned sale has an aggregate market value of $714,034.85, with MapLight reporting 42,620,000 common shares outstanding and an approximate sale date of July 15, 2026.

The shares come from several Restricted Stock Unit grants made between 2023 and 2025. Lillie has also sold MapLight shares over the prior three months, including 24,811 shares for $713,661.87 on May 6, 2026, along with additional smaller transactions in April and May 2026.

Key Figures

Shares planned for sale: 18,835 shares Aggregate market value of planned sale: $714,034.85 Shares outstanding: 42,620,000 shares +4 more

7 metrics

Shares planned for sale 18,835 shares Common stock to be sold through Jefferies LLC on NASDAQ

Aggregate market value of planned sale $714,034.85 Market value of 18,835 MapLight common shares planned for sale

Shares outstanding 42,620,000 shares MapLight Therapeutics common shares outstanding when sale was planned

Shares sold on May 6, 2026 24,811 shares MapLight common shares sold by James Lillie on 05/06/2026

Proceeds from May 6, 2026 sale $713,661.87 Aggregate proceeds from 24,811-share MapLight sale on 05/06/2026

Shares sold on May 4, 2026 15,801 shares MapLight common shares sold on 05/04/2026

Proceeds from May 4, 2026 sale $441,755.51 Aggregate proceeds from 15,801-share MapLight sale on 05/04/2026

Key Terms

Restricted Stock Unit Grant, Securities To Be Sold, Securities Sold During The Past 3 Months

3 terms

Restricted Stock Unit Grant financial

"Common | 05/02/2024 | Restricted Stock Unit Grant | Maplight"

Securities To Be Sold regulatory

"144: Securities To Be Sold"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is planned for MapLight Therapeutics (MPLT)?

James Lillie plans to sell up to 18,835 shares of MapLight Therapeutics common stock through Jefferies LLC. The planned sale has an aggregate market value of $714,034.85 and an approximate sale date of July 15, 2026.

How many MapLight Therapeutics (MPLT) shares are currently outstanding?

MapLight Therapeutics reports 42,620,000 shares of common stock outstanding. This provides context for the planned Rule 144 sale of 18,835 shares, showing the planned transaction represents a small portion of the company’s overall outstanding equity base.

What recent MapLight Therapeutics (MPLT) share sales has James Lillie made?

James Lillie has sold MapLight shares in several transactions, including 24,811 shares for $713,661.87 on May 6, 2026. Other disclosed sales occurred on April 15, April 16, May 4, May 5, and May 7, 2026.

What is the role of Jefferies LLC in the MapLight Therapeutics (MPLT) transaction?

Jefferies LLC is listed as the broker for the planned sale of 18,835 MapLight Therapeutics common shares. The shares are expected to be sold on the NASDAQ market around July 15, 2026, according to the disclosed details.

What is the source of the MapLight Therapeutics (MPLT) shares being sold?

The shares planned for sale come from several Restricted Stock Unit grants in 2023, 2024, and 2025. These grants include awards of 6,148, 3,200, 1,433, and 25,797 MapLight common shares to James Lillie.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 04:01 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001728746
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MapLight Therapeutics, Inc.
SEC File Number	001-42914
Address of Issuer	800 CHESAPEAKE DRIVE REDWOOD CITY CALIFORNIA 94063
Phone	650-839-4360
Name of Person for Whose Account the Securities are To Be Sold	Lillie James Woodruff
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	18835	714034.85	42620000	07/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/02/2024	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			6148	05/02/2024	N/A
Common	07/30/2023	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			3200	07/30/2023	N/A
Common	11/09/2023	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			1433	11/09/2023	N/A
Common	07/18/2025	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			25797	07/18/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Lillie 800 Chesapeake Drive Redwood City CA 94063	MapLight Therapeutics, Inc.	05/07/2026	721	20387.35
James Lillie 800 Chesapeake Drive Redwood City CA 94063	MapLight Therapeutics, Inc.	05/06/2026	24811	713661.87
James Lillie 800 Chesapeake Drive Redwood City CA 94063	MapLight Therapeutics, Inc.	05/05/2026	11095	312847.49
James Lillie 800 Chesapeake Drive Redwood City CA 94063	MapLight Therapeutics, Inc.	05/04/2026	15801	441755.51
James Lillie 800 Chesapeake Drive Redwood City CA 94063	MapLight Therapeutics, Inc.	04/16/2026	2783	76175.44
James Lillie 800 Chesapeake Drive Redwood City CA 94063	MapLight Therapeutics, Inc.	04/15/2026	1730	46398.27

144: Remarks and Signature

Remarks	Shares to be sold solely to satisfy tax-withholding obligations in connection w/ RSU vesting
Date of Notice	07/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Lillie
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)